A Retrospective Analysis on the Outcomes of Multiple Myeloma Patients with Del (17p) and/or TP53 Mutation in Asia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260118001

Enrollment

100

Registered

2026-01-18

Start date

2026-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma Del (17p) TP53 mutation multiple myeloma

Interventions

Patients with Del (17p) and/or TP53 Mutation

Diagnostic

Del (17p) or TP53 Mutation

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Individuals who are 18 years old or older 2. Diagnosed with active myeloma according to 2014 IMWG criteria 3. Patient must have measurable disease (quantifiable serum or urine M-protein) on diagnosis (defined as serum M protein more than or equal 0.5 g/dL or 24-hour urine M-protein excretion more than or equal 200mg or dFLC more than or equal 10 mg/dL (more than or equal 100 mg/L) or an abnormal serum free light chain ratio ( less than 0.26 or more than 1.65) 4. Documented del (17p) and/or TP53 mutation based on laboratory testing (e.g., FISH and/or NGS)

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with symptomatic amyloidosis, Waldenstrom macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) 2. Patients enrolled in clinical trials during any time point of their treatment

Design outcomes

Primary

Measure	Time frame
Overall Response Rate after each line of therapy during follow up Proportion of patients achieving partial response or better,Duration of Response From first documented response until progression death or last follow up Time from first achievement of partial response or better to disease progression or death,Progression Free Survival From diagnosis until progression Time from date of diagnosis to disease progression,Overall Survival From diagnosis until death ime from date of diagnosis to death	—

Measure

Time frame

Overall Response Rate after each line of therapy during follow up Proportion of patients achieving partial response or better,Duration of Response From first documented response until progression death or last follow up Time from first achievement of partial response or better to disease progression or death,Progression Free Survival From diagnosis until progression Time from date of diagnosis to disease progression,Overall Survival From diagnosis until death ime from date of diagnosis to death

—

Secondary

Measure	Time frame
Risk factors for Overall Survival From diagnosis until death or last follow up Association between baseline clinical cytogenetic and treatment related factors and overall survival,Minimal Residual Disease Negativity Rate Post treatment at documented response assessment Proportion of patients achieving MRD negativity,PET CT Response Post treatment at time of PET CT assessment Proportion of patients achieving metabolic response on PET CT	—

Measure

Time frame

Risk factors for Overall Survival From diagnosis until death or last follow up Association between baseline clinical cytogenetic and treatment related factors and overall survival,Minimal Residual Disease Negativity Rate Post treatment at documented response assessment Proportion of patients achieving MRD negativity,PET CT Response Post treatment at time of PET CT assessment Proportion of patients achieving metabolic response on PET CT

—

Countries

Thailand

Contacts

Public ContactChutima Kunacheewa

Faculty of Medicine Siriraj Hospital

chutima.kua@mahidol.ac.th024197767

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026